Published in Infect Control Hosp Epidemiol on October 03, 2007
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis (2008) 3.88
Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol (2008) 3.37
Burden of Clostridium difficile on the healthcare system. Clin Infect Dis (2012) 3.20
Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol (2008) 3.15
Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun (2011) 2.87
Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev (2011) 2.22
Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. Clin Drug Investig (2012) 2.03
Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One (2010) 1.87
Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol (2010) 1.82
The economic burden of Clostridium difficile. Clin Microbiol Infect (2011) 1.74
Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis (2008) 1.67
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol (2010) 1.58
Statin use and the risk of Clostridium difficile in academic medical centres. Gut (2012) 1.55
Antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg (2015) 1.47
Clostridium difficile-related hospitalizations among US adults, 2006. Emerg Infect Dis (2009) 1.39
Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of clostridium difficile disease. J Clin Microbiol (2010) 1.38
The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes (2010) 1.37
Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn (2011) 1.36
Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol (2009) 1.33
Mapping interactions between germinants and Clostridium difficile spores. J Bacteriol (2010) 1.29
Epidemiological model for Clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol (2011) 1.26
Incidence and Costs of Clostridium difficile Infections in Canada. Open Forum Infect Dis (2015) 1.22
Clostridium difficile toxins: mediators of inflammation. J Innate Immun (2012) 1.21
Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes (2010) 1.19
The impact of ICD-9-CM code rank order on the estimated prevalence of Clostridium difficile infections. Clin Infect Dis (2011) 1.16
The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology (2011) 1.15
Cyclic diguanylate inversely regulates motility and aggregation in Clostridium difficile. J Bacteriol (2012) 1.14
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract (2011) 1.11
Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol (2011) 1.08
A time-series analysis of clostridium difficile and its seasonal association with influenza. Infect Control Hosp Epidemiol (2010) 1.06
Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol (2011) 1.05
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother (2008) 1.05
A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol (2013) 1.03
Clostridium difficile in the ICU: the struggle continues. Chest (2011) 1.01
Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital. J Clin Microbiol (2011) 1.01
Vitamin D's potential to reduce the risk of hospital-acquired infections. Dermatoendocrinol (2012) 1.01
Clostridium difficile transcriptome analysis using pig ligated loop model reveals modulation of pathways not modulated in vitro. J Infect Dis (2011) 0.98
Increasing incidence of Clostridium difficile-associated disease, Singapore. Emerg Infect Dis (2008) 0.98
Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. J Clin Microbiol (2011) 0.98
Muricholic acids inhibit Clostridium difficile spore germination and growth. PLoS One (2013) 0.98
Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 0.97
The membrane as a target for controlling hypervirulent Clostridium difficile infections. J Antimicrob Chemother (2012) 0.96
The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge. Zoonoses Public Health (2010) 0.93
Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. Am J Physiol Gastrointest Liver Physiol (2014) 0.92
CodY-Dependent Regulation of Sporulation in Clostridium difficile. J Bacteriol (2016) 0.92
Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio (2015) 0.91
Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun (2011) 0.89
Association between prehospital vitamin D status and hospital-acquired Clostridium difficile infections. JPEN J Parenter Enteral Nutr (2014) 0.89
Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens. Ann Surg (2014) 0.88
Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis (2013) 0.87
Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen. Gut Microbes (2014) 0.86
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection. Antibiotics (Basel) (2015) 0.86
Clostridium difficile--a moving target. F1000 Med Rep (2011) 0.85
Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection. PLoS One (2016) 0.85
Initiation of sporulation in Clostridium difficile: a twist on the classic model. FEMS Microbiol Lett (2014) 0.84
SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother (2014) 0.84
Fecal transplantation for the treatment of recurrent clostridium difficile infection. N Am J Med Sci (2013) 0.83
Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries. Eur J Health Econ (2013) 0.83
Fecal transplant in refractory Clostridium difficile colitis. Dtsch Arztebl Int (2013) 0.83
Adherence to and Outcomes Associated with a Clostridium difficile Guideline at a Large Teaching Institution. Hosp Pharm (2015) 0.83
Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med (2016) 0.83
Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea. Therap Adv Gastroenterol (2014) 0.83
A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. BMC Infect Dis (2012) 0.82
Michigan Clostridium difficile hospital discharges: frequency, mortality, and charges, 2002-2008. Public Health Rep (2012) 0.81
Predictors of Clostridium difficile infection severity in patients hospitalised in medical intensive care. World J Gastroenterol (2013) 0.81
Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures. Acta Orthop (2010) 0.81
Community-Acquired Clostridium Difficile Infection: Awareness and Clinical Implications. J Nurse Pract (2013) 0.80
Clostridium difficile glutamate dehydrogenase is a secreted enzyme that confers resistance to H2O2. Microbiology (2013) 0.80
Prolongation of length of stay and Clostridium difficile infection: a review of the methods used to examine length of stay due to healthcare associated infections. Antimicrob Resist Infect Control (2012) 0.80
Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. Can J Infect Dis Med Microbiol (2014) 0.80
Clostridium difficile Infection and Patient-Specific Antimicrobial Resistance Testing Reveals a High Metronidazole Resistance Rate. Dig Dis Sci (2017) 0.79
Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Clin Exp Gastroenterol (2013) 0.79
Economic evaluation of laboratory testing strategies for hospital-associated Clostridium difficile infection. J Clin Microbiol (2013) 0.78
Prevalence and impact of Clostridium difficile infection in elderly residents of long-term care facilities, 2011: A nationwide study. Medicine (Baltimore) (2016) 0.78
Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries. Infect Dis Clin Pract (Baltim Md) (2015) 0.77
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells. Bioorg Med Chem Lett (2013) 0.77
Vitamin D deficiency is associated with community-acquired clostridium difficile infection: a case-control study. BMC Infect Dis (2014) 0.77
A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters. Hum Vaccin Immunother (2015) 0.77
Clostridium difficile infection in the community: are proton pump inhibitors to blame? World J Gastroenterol (2013) 0.77
Implementation of Polymerase Chain Reaction to Rule Out Clostridium difficile Infection Is Associated With Reduced Empiric Antibiotic Duration of Therapy. Hosp Pharm (2014) 0.76
A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015. Public Health Rep (2016) 0.76
Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile. MBio (2016) 0.76
Isolation of C. difficile Carriers Alone and as Part of a Bundle Approach for the Prevention of Clostridium difficile Infection (CDI): A Mathematical Model Based on Clinical Study Data. PLoS One (2016) 0.76
In Vitro Selection of a Single-Stranded DNA Molecular Recognition Element against Clostridium difficile Toxin B and Sensitive Detection in Human Fecal Matter. J Nucleic Acids (2015) 0.76
Clostridium difficile: an emerging pathogen in children. Discov Med (2012) 0.75
The impact of Clostridum difficile on surgical rate among ulcerative colitis patients: A systemic review and meta-analysis. Saudi J Gastroenterol (2015) 0.75
Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis (2016) 0.75
Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study. BMC Geriatr (2016) 0.75
A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PLoS One (2015) 0.75
A New Lab Developed Real Time PCR Assay for Direct Detection of C. Difficle from Stool Sample without DNA Extraction. Int J Biomed Sci (2016) 0.75
Racial Differences in Clostridium difficile Infection Rates Are Attributable to Disparities in Health Care Access. Antimicrob Agents Chemother (2015) 0.75
Fidaxomicin--the new drug for Clostridium difficile infection. Indian J Med Res (2015) 0.75
Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings. Emerg Infect Dis (2016) 0.75
Antimicrobial Stewardship for a Geriatric Behavioral Health Population. Antibiotics (Basel) (2016) 0.75
Intestinal Organoids: New Frontiers in the Study of Intestinal Disease and Physiology. J Pediatr Gastroenterol Nutr (2016) 0.75
Interspecies Interactions between Clostridium difficile and Candida albicans. mSphere (2016) 0.75
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. Value Health (2012) 2.86
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone (2005) 2.66
Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension (2006) 2.46
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making (2012) 2.21
QALYs: are they helpful to decision makers? Pharmacoeconomics (2006) 1.67
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis (2006) 1.59
Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe (2009) 1.47
Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res (2003) 1.42
Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol (2006) 1.30
Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion (2007) 1.27
Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making (2012) 1.22
Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J (2005) 1.19
Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis (2005) 1.13
Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. Value Health (2012) 1.05
The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: a qualitative review of the literature. Curr Med Res Opin (2007) 1.05
Long term cost-of-illness in stroke: an international review. Pharmacoeconomics (2002) 1.01
Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One (2009) 0.97
The prognostic value of the modified Rankin Scale score for long-term survival after first-ever stroke. Results from the Athens Stroke Registry. Cerebrovasc Dis (2008) 0.95
Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics (2009) 0.95
Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother (2002) 0.93
Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney Int (2005) 0.90
Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health (2005) 0.89
Meta-analysis of longitudinal studies. Clin Trials (2007) 0.89
Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr Infect Dis J (2002) 0.87
Medical planning and response for a nuclear detonation: a practical guide. Biosecur Bioterror (2012) 0.87
Scarce resources for nuclear detonation: project overview and challenges. Disaster Med Public Health Prep (2011) 0.86
Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharmacoeconomics (2005) 0.84
Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K. Cost Eff Resour Alloc (2004) 0.84
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. Value Health (2009) 0.84
Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Curr Med Res Opin (2007) 0.82
Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health (2009) 0.82
Describing cognitive decline of patients at the mild or moderate stages of Alzheimer's disease using the Standardized MMSE. Int Psychogeriatr (2002) 0.80
Economic and health consequences of managing bradycardia with dual-chamber compared to single-chamber ventricular pacemakers in Italy. J Cardiovasc Med (Hagerstown) (2008) 0.79
Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther (2003) 0.79
An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol (2002) 0.79
Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations. Pharmacoeconomics (2005) 0.79
User-managed inventory: an approach to forward-deployment of urgently needed medical countermeasures for mass-casualty and terrorism incidents. Disaster Med Public Health Prep (2012) 0.79
The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism. Int J Dermatol (2007) 0.78
Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin (2010) 0.78
Summary: health and economic burden of pertussis. Pediatr Infect Dis J (2005) 0.78
Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Curr Hypertens Rep (2002) 0.78
Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care. Am J Med Qual (2007) 0.78
Evaluating the true cost of hypertension management: evidence from actual practice. Expert Rev Pharmacoecon Outcomes Res (2004) 0.77
A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. Pharmacoeconomics (2011) 0.77
Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences. Value Health (2008) 0.77
Managing meningococcal disease in the United States: Hospital case characteristics and costs by age. Value Health (2006) 0.77
Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther (2004) 0.77
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health (2011) 0.76
Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics (2002) 0.76
Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics (2013) 0.76
A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial. Br J Clin Pharmacol (2008) 0.75
Ignoring study design heterogeneity in meta-analyses. Arch Intern Med (2006) 0.75
Cost-effectiveness of cardiac resynchronization therapy. J Am Coll Cardiol (2006) 0.75
Systematic review of the effects of pertussis vaccines in children. Vaccine (2004) 0.75
The Hanover Consensus: helpful for German decision-makers? Value Health (2008) 0.75
Regarding probabilistic analysis and computationally expensive models: necessary and required? Value Health (2007) 0.75
Methods of economic evaluation for the German statutory healthcare system. Pharmacoeconomics (2009) 0.75
An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 24). Curr Hypertens Rep (2002) 0.75
Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia. Clin Ther (2008) 0.75
Use of relative effectiveness information in reimbursement and pricing decisions in Europe. J Comp Eff Res (2013) 0.75
Economic assessments of low molecular weight heparin in venous thromboembolism. Expert Rev Pharmacoecon Outcomes Res (2004) 0.75
The budget impact of controlling wastage with smaller vials: A data driven model of session sizes in Bangladesh, India (Uttar Pradesh),Mozambique, and Uganda. Vaccine (2014) 0.75
Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial. Can J Cardiol (2011) 0.75
An interview with J. Jaime Caro. Am J Manag Care (2004) 0.75
Pharmacoutilization of antihypertensive drugs: a model of analysis. Curr Hypertens Rep (2002) 0.75
Economic implications of growth hormone use in patients with short bowel syndrome. Curr Med Res Opin (2006) 0.75
How relevant is cost-effectiveness anyway? Eur Heart J (2013) 0.75
Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. Curr Hypertens Rep (2002) 0.75